Efficacy and Safety of Befotertinib

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR ...

Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation ...

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR ...

Conclusions. Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC ...

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR ...

Conclusions. Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M ...

Befotertinib (D-0316) versus icotinib as first-line therapy for patients ...

Lu, S ∙ Zhang, Y ∙ Zhang, G ∙ et al. Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC that had ...

Efficacy of befotertinib in non-small cell lung cancer harboring ...

Befotertinib was effective and safe in the treatment of NSCLC patients with rare p.G719X/p.S768I complex mutations and might be a promising ...

LBA6 Befotertinib (D-0316) versus icotinib as first-line therapy for ...

This phase III, open-label, randomized trial was conducted to compare the efficacy and safety of befotertinib versus icotinib as first-line treatment in pts ...

Befotertinib (D-0316) versus icotinib as first-line therapy for patients ...

The purpose of this study was to evaluate the efficacy and safety of befotertinib in untreated patients with EGFR-mutated locally advanced or metastatic NSCLC.

Befotertinib for patients with pretreated EGFR T790M mutated locally ...

Herein, we present the final OS and safety data. Results. A total of 176 patients in cohort A and 290 patients in cohort B were finally enrolled. At data cutoff ...

EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR ...

Befotertinib has shown favorable efficacy and manageable safety in pts with locally advanced or metastatic NSCLC harboring T790M mutation as a second-line ...

Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?

9. Cho, BC ∙ Ahn, M-J ∙ Kang, JH ∙ et al. LBA7—a randomized, double-blind, multinational phase III study to assess the efficacy and safety ...

LBA9 Final overall survival (OS) results of befotertinib in patients ...

Overall, befotertinib maintained its remarkable efficacy with a manageable safety profile in pretreated pts with confirmed T790M mutation-positive NSCLC.

Efficacy and safety of befotertinib (D-0316) in patients with EGFR ...

Conclusion: Befotertinib of 75-100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC ...

Mini oral session 2: Thoracic cancer - OncologyPRO

LBA9 - Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non- ...

Befotertinib (D-0316) versus icotinib as first-line therapy for patients ...

This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as a first-line... There was an error loading this content. Please refresh ...

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer ...

... efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) ...

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR ...

Article "Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase ...

Befotertinib in first-line treatment for Chinese non-small cell lung ...

... lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile.

ESMO Asia Congress 2022 | OncologyPRO

This phase III, open-label, randomized trial was conducted to compare the efficacy and safety ... Befotertinib demonstrated superior efficacy compared with ...

Efficacy and safety of re-challenging 160 mg furmonertinib for ...

... befotertinib), including treatment using the combination of vascular-targeting agents and chemotherapy during the same period. Patients did ...

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

... Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs open_in_new. J Thorac Oncol 2022 - Efficacy and safety of befotertinib (D-0316) ...